![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon / ribavirin treatment: Virologic analyses of the ASPIRE trial
|
|
|
Reported by Jules Levin
EASL 2012 April18-22 Barcelona Spain
Oliver Lenz,1Bart Fevery,1Leen Vijgen,1Jannick Verbeeck,1Monika Peeters,1Maria Beumont-Mauviel,1Stefan Zeuzem,2Gaston Picchio3
1Janssen Infectious Diseases BVBA, Beerse, Belgium; 2Department of Medicine I, JW Goethe University Hospital, Frankfurt, Germany; 3Janssen Research and Development LLC, Titusville, NJ, USA
![EASL1.gif](../images/041812/041912-6/EASL1.gif)
![EASL2.gif](../images/041812/041912-6/EASL2.gif)
![EASL3.gif](../images/041812/041912-6/EASL3.gif)
![EASL4.gif](../images/041812/041912-6/EASL4.gif)
![EASL5.gif](../images/041812/041912-6/EASL5.gif)
![EASL6.gif](../images/041812/041912-6/EASL6.gif)
![EASL7.gif](../images/041812/041912-6/EASL7.gif)
![EASL8.gif](../images/041812/041912-6/EASL8.gif)
![EASL9.gif](../images/041812/041912-6/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|